NYSEMKT: NBY
Novabay Pharmaceuticals Inc Stock

$0.67+0.02 (+3.08%)
Updated Feb 13, 2025
NBY Price
$0.67
Fair Value Price
N/A
Market Cap
$3.27M
52 Week Low
$0.36
52 Week High
$9.08
P/E
-0.01x
P/B
3.05x
P/S
0.23x
PEG
N/A
Dividend Yield
N/A
Revenue
$11.20M
Earnings
-$10.12M
Gross Margin
60.7%
Operating Margin
-90.36%
Profit Margin
-147.9%
Debt to Equity
2.62
Operating Cash Flow
-$5M
Beta
0.55
Next Earnings
Mar 24, 2025
Ex-Dividend
N/A
Next Dividend
N/A

NBY Overview

NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing products for the eye care market. The company is headquartered in Emeryville, California and currently employs 70 full-time employees. The firm focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is an eye care product formulated with a form of hypochlorous acid called Neutrox. Its Avenova with Neutrox removes debris from the skin on the eyelids and lashes without burning or stinging. The company develops additional products containing Neutrox, including its NeutroPhase Skin and Wound Cleanser for wound care and CelleRx for the dermatology market. Its Aganocide compounds, led by auriclosene (NVC-422), are synthetic molecules with activity against bacteria, viruses and fungi. The firm's dermatology product includes CelleRx, a cleansing solution for post laser resurfacing, chemical peels and other cosmetic surgery procedures. Its wound care business includes the business of NeutroPhase product.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine NBY's potential to beat the market

CHold
  • Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More

Zen Rating Component Grades

F
Value
B
Growth
F
Momentum
C
Sentiment
D
Safety
D
Financials
F
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
NBY
Ranked
#249 of 560

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important NBY news, forecast changes, insider trades & much more!

NBY News

Overview

Due Diligence Score

Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how NBY scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

NBY is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
NBY is good value based on its book value relative to its share price (3.05x), compared to the US Biotechnology industry average (4.78x)
P/B vs Industry Valuation
NBY is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more NBY due diligence checks available for Premium users.

Valuation

NBY price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-0.01x
Industry
-174.82x
Market
38.39x

NBY price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
3.05x
Industry
4.78x
NBY is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

NBY's financial health

Profit margin

Revenue
$2.4M
Net Income
-$1.2M
Profit Margin
-90.8%
NBY's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
NBY's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$3.9M
Liabilities
$2.8M
Debt to equity
2.62
NBY's short-term assets ($2.28M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NBY's short-term assets ($2.28M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NBY's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
NBY's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$2.1M
Investing
-$2.0k
Financing
$2.1M
NBY's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

NBY vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
NBYC$3.27M+3.08%-0.01x3.05x
LIXTC$3.15M-17.65%-0.81x2.30x
KZIA$3.13M-4.08%-0.14x-0.48x
NCNA$3.48M+2.67%-0.06x0.63x
MTNBC$3.05M+2.39%-0.12x0.19x

Novabay Pharmaceuticals Stock FAQ

What is Novabay Pharmaceuticals's quote symbol?

(NYSEMKT: NBY) Novabay Pharmaceuticals trades on the NYSEMKT under the ticker symbol NBY. Novabay Pharmaceuticals stock quotes can also be displayed as NYSEMKT: NBY.

If you're new to stock investing, here's how to buy Novabay Pharmaceuticals stock.

What is the 52 week high and low for Novabay Pharmaceuticals (NYSEMKT: NBY)?

(NYSEMKT: NBY) Novabay Pharmaceuticals's 52-week high was $9.08, and its 52-week low was $0.36. It is currently -92.62% from its 52-week high and 85.6% from its 52-week low.

How much is Novabay Pharmaceuticals stock worth today?

(NYSEMKT: NBY) Novabay Pharmaceuticals currently has 4,885,693 outstanding shares. With Novabay Pharmaceuticals stock trading at $0.67 per share, the total value of Novabay Pharmaceuticals stock (market capitalization) is $3.27M.

Novabay Pharmaceuticals stock was originally listed at a price of $110,862.50 in Oct 26, 2007. If you had invested in Novabay Pharmaceuticals stock at $110,862.50, your return over the last 17 years would have been -100%, for an annualized return of -50.68% (not including any dividends or dividend reinvestments).

How much is Novabay Pharmaceuticals's stock price per share?

(NYSEMKT: NBY) Novabay Pharmaceuticals stock price per share is $0.67 today (as of Feb 13, 2025).

What is Novabay Pharmaceuticals's Market Cap?

(NYSEMKT: NBY) Novabay Pharmaceuticals's market cap is $3.27M, as of Feb 14, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Novabay Pharmaceuticals's market cap is calculated by multiplying NBY's current stock price of $0.67 by NBY's total outstanding shares of 4,885,693.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.